SSP

Serious Shortage Protocols for fluoxetine 30mg capsules and Salazopyrin® EN-Tabs 500mg

Serious Shortage Protocols (SSPs) have been issued for fluoxetine 30mg capsules and Salazopyrin® EN-Tabs 500mg. 

Serious Shortage Protocols (SSPs) have been issued for fluoxetine 30mg capsules and Salazopyrin® EN-Tabs 500mg.

The fluoxetine 30mg capsules SSP will enable community pharmacists in England and Wales to supply patients with 1 x 20mg fluoxetine capsule and 1 x 10mg fluoxetine capsule OR 3 x 10mg fluoxetine capsules. This SSP is due to expire on 22 December 2020.

The Salazopyrin® EN-Tabs 500mg SSP will enable community pharmacists in England and Wales to supply sulfasalazine 500mg gastro-resistant (GR) tablets. This SSP is due to expire on 4 December 2020.

These SSPs and supporting guidance are now published on the NHS Business Service Authority's (NHSBSA's) website. If the current end dates change, the SSPs will be updated accordingly.

To access the latest information about SSPs (including supporting guidance), visit the website.

Contact Information

Kate Blush

Media and Campaigns Officer

NHS Business Services Authority

nhsbsa.communicationsteam@nhs.net

Notes to editors

About the NHS Business Services Authority

The NHS Business Services Authority is a Special Health Authority and an Arm’s Length Body of the Department of Health and Social Care which provides a range of critical central services to NHS organisations, NHS contractors, patients and the public. Its purpose is to be a catalyst for better health and its vision is to be the delivery partner of choice for the NHS. For more information about the NHSBSA, please visit www.nhsbsa.nhs.uk